The Latest
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Three biotechs supported by the venture firms BioPharma Dive tracks raised funds during JPM week. The largest round went to Mirador Therapeutics, an immune drug startup led by former Prometheus Biosciences executives.
Updated Jan. 16, 2026 -
ShutterStock/PeopleImages
Sponsored by Cryopak Inc.Building more sustainable cold chain packaging through innovation
Working towards the future of cold chain packaging: sustainable packaging without performance tradeoffs.
-
Getty Images
Tecvayli tops standard drugs in early multiple myeloma, J&J says
The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.
-
Samuel Corum via Getty Images
Trump unveils healthcare affordability plan
The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the administration has cut with more than a dozen drugmakers.
-
Kendall Davis/BioPharma Dive
Tracker10 clinical trials to watch in the first half of 2026
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.
-
Andrew Harnik via Getty Images
Obesity drugsLilly, chasing Novo, expects second-quarter FDA decision on obesity pill
Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”
-
Getty Images
Oxford Biomedica confirms takeover talks with biotech investor EQT
Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited take-private bids from EQT that it felt “undervalued” the company and its prospects.
-
Courtesy of Boston Scientific
Boston Scientific to acquire Penumbra for $14.5B
With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.
-
Getty Images
Startup launchesCaldera starts up with $112.5M and a dual-targeting immune drug from China
The biotech is advancing a bispecific medicine aimed at two popular targets and being billed as a potential therapeutic advance for inflammatory bowel disease.
-
Alamy
Trump administrationAbbVie pledges $100B to US production in drug pricing deal with Trump
As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on details as well as its potential financial impact.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
The roughly $1.1 billion in private funding Eikon raised before seeking an IPO would rank as the most of any drugmaker that’s gone public since Moderna in 2018, BioPharma Dive data show.
Updated Jan. 13, 2026 -
Alamy
IPO windowEikon, a high-profile startup led by Merck vets, seeks an IPO
Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a group of experimental cancer drugs.
-
Getty Images
Digital health funding increases in 2025, spurred by AI: report
Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total funding, according to Rock Health.
-
Alamy
Trump administration5 FDA decisions to watch in the first quarter of 2026
By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it rejected two years ago.
-
Permission granted by Sanofi
What Sanofi’s multiple sclerosis troubles could mean for the space
Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact.
-
Permission granted by Aurora Therapeutics
Gene editingAurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.
-
Getty Images
News roundupAbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.
-
Getty Images
IPO windowAktis raises $318M in 2026’s first biotech IPO
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Novartis and AbbVie both linked up with China-based drugmakers on Monday, adding to two licensing announcements from Roche and startup AirNexis Therapeutics on Friday.
Updated Jan. 9, 2026 -
Getty Images
News roundup
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal
Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.
-
Getty Images
Obesity drugsAlveus launches with $160M to advance MariTide-like obesity drug
The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as well as an amylin-targeting weight loss medicine.
-
Scott Olson via Getty Images
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs
The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an array of conditions.
Updated Jan. 8, 2026 -
Permission granted by FogPharma
Emerging biotechParabilis, chasing ‘undruggable’ targets, nabs $305M amid VC funding blitz
The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the top of 2026.
-
Permission granted by Diagonal Therapeutics
Emerging biotechDiagonal banks another $125M for ‘clustering’ antibody drugs
Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of treating two disparate conditions, one of which is the target of Merck’s fast-selling Winrevair.
-
Getty Images
GSK, Ionis claim study success for RNA-based hepatitis B drug
The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.
-
Getty Images
Emerging biotechEpiBiologics raises $107M for its protein-degrading cancer drug
The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of several marketed therapies.
